管理高风险药物相互作用与涅马特雷尔维尔/里托纳维尔:从专门的药理咨询服务的经验
Youssef Libiad1, Bénédicte Franck1,2, Camille Tron1,2,3
1Univ Rennes, Service de Pharmacologie Biologique, CHU Rennes, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail) - UMR S 1085, Rennes, France.
Clinical and translational science
|March 3, 2026
概括
尼尔马特里尔维尔/里托纳维尔对COVID-19至关重要,但里托纳维尔会引起药物相互作用. 法国专家系统有助于管理老年患者的这些相互作用,使大多数人能够安全处方.
科学领域:
- 临床药理学 临床药理学
- 传染性疾病 传染性疾病
- 药物相互作用 药物相互作用
背景情况:
- 尼尔马特里尔维尔/里托纳维尔是一种重要的COVID-19抗病毒.
- 里托纳维尔的CYP3A4抑制导致显著的药物相互作用 (DDI).
- 管理DDI至关重要,特别是在老年,多种药物治疗的患者中.
研究的目的:
- 评估法国国家积极主动专家药理咨询系统的经验.
- 评估对尼尔马特里尔维尔/里托纳维尔处方药物相互作用的管理.
- 确定在复杂患者群体中使用涅马特里尔维尔/里托纳维尔的安全性和可行性.
主要方法:
- 在2022年2月至2024年12月期间,对455名患者进行了回顾性研究,这些患者接受了对nirmatrelvir/ritonavir的专家药理咨询.
- 分析患者人口统计,并发药物和确定的DDI.
- 管理策略的评估,包括联合药物调整和监测.
主要成果:
- 86.7%的符合条件的患者 (429) 至少有一次临床相关的DDI.
- 类药物,免疫抑制剂和直接口服抗凝剂是最常见的相互作用药物类别.
- 专家建议通过联合药物管理和监测,在大多数患者中促进了nirmatrelvir/ritonavir的使用.
结论:
- 尼尔马特雷尔维尔/里托纳维尔的DDI患病率很高,特别是在老年患者中.
- 积极的临床药理学支持对于安全处方易发生相互作用的疗法至关重要.
- 该模型支持在多种药物治疗群体中复杂药物治疗方案的决策.
相关概念视频
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
383
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
383
Pharmacokinetics: Drug–Drug Interactions
545
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
545
Drug toxicity: Drug–Drug Interaction
124
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
124
Myocarditis III: Medical Management
268
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
268
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
318
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
318
Therapeutic Drug Monitoring: Affecting Factors
293
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
293


